Are more immuno-oncology buyouts on the menu at Eli Lilly’s executive suite?
Flush with cash following the Elanco spinoff, Eli Lilly execs are talking up the chances of executing more near-term buyouts like their $1.6 billion Armo acquisition earlier this year.
Company CFO Joshua Smiley told Reuters that they are steering clear of the Big Pharma mergers — no surprise there — while reiterating the recent talk at Lilly about executing some new acquisitions after relying largely on its internal pipeline for new product development.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.